There are five steps in the drug development process, which are designed to help ensure that potential new therapies are both safe and effective. Developing medical products for rare diseases encounters many challenges throughout this process. The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) is being developed by NORD and the Critical Path Institute (C-Path) to help overcome these hurdles. This will help contribute to faster development of medications for rare diseases, 90% of which are still without an FDA-approved treatment. Together, NORD and C-Path have created a three-part video series, “Accelerating Rare Disease Drug Development,” with video #1 addressing the basics of the drug development process. Watch the video or learn more about the RDCA-DAP here: https://rarediseases.org/rdca-dap/
